Form 4: Stoke Therapeutics' Chief Medical Officer Executes Stock Option and Sells Shares

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, exercised stock options and sold 10,000 shares of common stock on November 1, 2024, according to a Form 4 filing with the SEC.

Summary

• On November 1, 2024, Barry Ticho, the Chief Medical Officer of Stoke Therapeutics, exercised a stock option to purchase 10,000 shares of common stock at a price of $0.60 per share.
• Simultaneously, Ticho sold 10,000 shares of Stoke Therapeutics' common stock at a weighted average price of $12.6803 per share, with individual sales ranging from $12.43 to $12.90.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 14, 2023.
• Following these transactions, Ticho directly owns 2,485 shares of common stock and 10,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects routine transactions under a pre-existing trading plan. There's no indication of unusual or concerning activity.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like the Chief Medical Officer, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects. The use of a 10b5-1 trading plan suggests the insider is selling shares according to a pre-arranged schedule to avoid accusations of trading on inside information.

Key Dates